Literature DB >> 26808567

Conjunctival polyploid cells and donor-derived myofibroblasts in ocular GvHD.

D Hallberg1, K Stenberg2, C Hanson3, U Stenevi2, M Brune1.   

Abstract

After allogeneic hematopoietic stem cell transplantation (allo-SCT), ocular GvHD is a common complication, typical symptoms being dry eye syndrome with features of fibrosis. In this study, we have identified and quantified two cell types-myofibroblasts (MFB) and polyploid (PP) cells-in the conjunctival surface of allo-SCT patients (pts) and have explored their kinetics and association with local and systemic GvHD. Results are compared with control groups of (a) pretransplant samples from allo-SCT patients, (b) recipients of autologous transplantation (auto-SCT) and (c) healthy controls. Imprint cytologies were obtained by pressing the conjunctival surface with a sterile, non-abrasive cellulose acetate filter (Millipore). After retraction, typically a monolayer of the outermost cells of the epithelium were retrieved. MFB were identified by immunofluorescent (IF) staining for alpha-smooth muscle protein. PP cells were detected by aberrant chromosome content analyzed via X/Y-FISH (X/Y fluorescence in situ hybridization). In female pts with a male donor (MF group), donor genotype were identified by sex chromosome detection using FISH methodology. IF and FISH methods were applied in situ on the same filter, and amounts of MFB and PP cells are expressed as the percentage of all cells on the filter. In all, 70 samples from 46 pts were obtained 1-122 months after allo-SCT. The total MFB density (MFB(TOT)) was higher in allo-SCT pts compared with healthy individuals and auto-SCT pts and increased by time after transplantation (P<0.001). In MF recipients, this increase proved to be due to a significant (P<0.001) and gradual elevation of donor-derived MFB (MFB(XY)), whereas recipient-derived MFB (MFB(XX)) did not vary over time. Clinical ocular GvHD correlated with MFB(XY)/MFB(TOT) ratio (P=0.034), whereas no association between MFB(TOT) or MFB(XY) systemic GvHD was observed. In the MF group (n=25), both MFB(XY) and MFB(XX) were detected on 28 of the 37 imprints (76%). In pts >36 months post transplant, on 11/12 imprints, a median of 9.4% (1.4-39%) MFB(XY) and 3.6% (0-11%) MFB(XX) was found. In one patient, 1.6% MFB(XY) were detected at 3 weeks post transplant. PP cells (6-24n), exclusively of recipient origin, were found to a median of 0.6% (0-37%). The PP cell density differed significantly (P<0.001) between time intervals, with a maximum 8.9% (0-35%) of all cells at 3-12 months. No correlation between PP cells and GvHD (ocular or systemic) was observed. The MFB has been indicated as a culprit in chronic inflammation and fibrosis. The observation that MFB(XY)/MFB(TOT) ratio correlated with ocular GvHD suggests a role of donor MFB in GvHD pathogenesis. The constant finding of recipient-derived MFB(XX) cells many years after transplant in pts with 100% donor hematopoiesis indicates that there is a non-hematopoietic differentiation route to MFB. The origin and role of PP cells after allo-SCT remains obscure.

Entities:  

Mesh:

Year:  2016        PMID: 26808567     DOI: 10.1038/bmt.2015.347

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  20 in total

1.  Myofibroblasts in the normal conjunctival surface.

Authors:  Ximena Aguilar; David Hallberg; Karin Sundelin; Charles Hanson; Kristina Stenberg; Mats Brune; Ulf Stenevi
Journal:  Acta Ophthalmol       Date:  2009-09-11       Impact factor: 3.761

2.  Donor fibroblast chimerism in the pathogenic fibrotic lesion of human chronic graft-versus-host disease.

Authors:  Yoko Ogawa; Hiroaki Kodama; Kaori Kameyama; Kazuto Yamazaki; Hidekata Yasuoka; Shinichiro Okamoto; Hidetoshi Inoko; Yutaka Kawakami; Masataka Kuwana
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-12       Impact factor: 4.799

3.  A Wilcoxon-type test for trend.

Authors:  J Cuzick
Journal:  Stat Med       Date:  1985 Jan-Mar       Impact factor: 2.373

4.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

Review 5.  Fibrocytes in health and disease.

Authors:  Erica L Herzog; Richard Bucala
Journal:  Exp Hematol       Date:  2010-03-18       Impact factor: 3.084

6.  Replicative senescence of human endothelial cells in vitro involves G1 arrest, polyploidization and senescence-associated apoptosis.

Authors:  M Wagner; B Hampel; D Bernhard; M Hala; W Zwerschke; P Jansen-Dürr
Journal:  Exp Gerontol       Date:  2001-08       Impact factor: 4.032

7.  Fibrosis: recent advances in myofibroblast biology and new therapeutic perspectives.

Authors:  Boris Hinz; Giulio Gabbiani
Journal:  F1000 Biol Rep       Date:  2010-11-11

8.  Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation.

Authors:  Masataka Kuwana; Yuka Okazaki; Hiroaki Kodama; Keisuke Izumi; Hidekata Yasuoka; Yoko Ogawa; Yutaka Kawakami; Yasuo Ikeda
Journal:  J Leukoc Biol       Date:  2003-07-22       Impact factor: 4.962

Review 9.  Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation.

Authors:  Yoko Ogawa; Masataka Kuwana
Journal:  Cornea       Date:  2003-10       Impact factor: 2.651

Review 10.  Human circulating monocytes as multipotential progenitors.

Authors:  Noriyuki Seta; Masataka Kuwana
Journal:  Keio J Med       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.